Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NR...

Podrobná bibliografie
Hlavní autoři:	Gupta, V, Kosiorek, H, Mead, A, Klisovic, R, Galvin, J, Berenzon, D, Yacoub, A, Viswabandya, A, Mesa, R, Goldberg, J, Price, L, Salama, M, Weinberg, R, Rampal, R, Farnoud, N, Dueck, A, Mascarenhas, J, Hoffman, R
Médium:	Journal article
Jazyk:	English
Vydáno:	Elsevier 2018

Podobné jednotky

Practical management of patients with myelofibrosis receiving ruxolitinib.
Autor: Harrison, C, a další
Vydáno: (2013)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
Autor: V. Gupta, a další
Vydáno: (2022-06-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Autor: Srdan Verstovsek, a další
Vydáno: (2023-07-01)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
Autor: O. G. Golovina, a další
Vydáno: (2024-11-01)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
Autor: C. Harrison, a další
Vydáno: (2022-06-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
Autor: J. Mascarenhas, a další
Vydáno: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Autor: Butt, N, a další
Vydáno: (2019)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Autor: Harrison, C, a další
Vydáno: (2016)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
Autor: Claire Harrison
Vydáno: (2015-04-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
Autor: C. Harrison, a další
Vydáno: (2022-06-01)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
Autor: David M. Ross, a další
Vydáno: (2021-01-01)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
Autor: C. Harrison, a další
Vydáno: (2022-06-01)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Autor: Naval Daver, a další
Vydáno: (2015-08-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
Autor: F. Palandri, a další
Vydáno: (2022-06-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
Autor: Maheen Z. Abidi, a další
Vydáno: (2016-01-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
Autor: Antoine El Kik, a další
Vydáno: (2024-01-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
Autor: Sunny Sandhu, a další
Vydáno: (2022-01-01)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
Autor: Robert Peter Gale, a další
Vydáno: (2024-07-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
Autor: P. Harrington, a další
Vydáno: (2022-06-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
Autor: Eylem Eliaçık, a další
Vydáno: (2015-05-01)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
Autor: Douglas Tremblay, a další
Vydáno: (2019-01-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
Autor: O'Sullivan, JM, a další
Vydáno: (2023)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
Autor: Tim Kong, a další
Vydáno: (2024-03-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
Autor: Leona Dold, a další
Vydáno: (2021-09-01)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
Autor: Yosuke Okada, a další
Vydáno: (2024-06-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Autor: Bewersdorf JP, a další
Vydáno: (2019-12-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
Autor: Maymona G. Abdelmagid, a další
Vydáno: (2023-02-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
Autor: Z. Xu, a další
Vydáno: (2022-06-01)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
Autor: J. Mei, a další
Vydáno: (2022-06-01)

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche
Autor: Juo-Chin Yao, a další
Vydáno: (2022-06-01)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
Autor: Elsemieke te Linde, a další
Vydáno: (2022-11-01)

Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections
Autor: Chia-Yu Chiu, a další
Vydáno: (2024-03-01)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Autor: Moshe Talpaz, a další
Vydáno: (2018-08-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
Autor: Claire Harrison, a další
Vydáno: (2022-08-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
Autor: Vera Stoeva, a další
Vydáno: (2023-07-01)

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review
Autor: GUO Huimei, a další
Vydáno: (2018-08-01)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
Autor: D. Cattaneo, a další
Vydáno: (2022-06-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
Autor: Marina Kremyanskaya, a další
Vydáno: (2023-08-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Autor: María Teresa Gómez-Casares, a další
Vydáno: (2017-11-01)

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Autor: Vikas Gupta, a další
Vydáno: (2016-12-01)